検索したら2015年の解説論文を見つけた:AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy | Journal of Hematology & Oncology https://t.co/LNe2cuqKTF https://t.co/c6YTMG465w
6,701 followers
3,925 followers
@Biotech2k1 @PhilippBaer1 @sububoston @YuZhu4 @PersimmonTI OK - I see you're willing to learn - so you win - Affimed ICE are not Bi-Specifics because tetravalent so lets name it with the reviewers first-in-class "AFM13 is a tetravalent bsAb against CD30 a
3,925 followers
@PhilippBaer1 @Biotech2k1 @sububoston @YuZhu4 @PersimmonTI Yeap - and sure $AFMD Affimed owns an antibody company https://t.co/zCeBU14m5C specialized in phage display and optimizations for many partners including Affimed themself. For a 3rd party explanat
2,272 followers
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunoth... https://t.co/zAlV0Vlwzj #jhoonline